Category: Uncategorized

Uncategorized

General

Guest Commentary: What Might a Part B IPI Model Do to Drug Innovation, Patient Care?

Guest Commentary: What Might a Part B IPI Model Do to Drug Innovation, Patient Care?

By Michael Parenti, Senior Engagement Strategist, Saatchi & Saatchi Wellness Feb. 1, 2019 — On Oct. 25, 2018, the Centers for Medicare and Medicaid Services (CMS) issued an advance notice of proposed rulemaking (ANPRM) to test whether phasing down the Medicare payment amount for selected Part B drugs to more closely align with international prices […]

Read more